Repositioning Candidate Details
| Candidate ID: | R0097 |
| Source ID: | DB00263 |
| Source Type: | approved; vet_approved |
| Compound Type: | small molecule |
| Compound Name: | Sulfisoxazole |
| Synonyms: | 3,4-Dimethyl-5-sulfanilamidoisoxazole; 3,4-Dimethyl-5-sulfonamidoisoxazole; 3,4-Dimethyl-5-sulphanilamidoisoxazole; 3,4-Dimethyl-5-sulphonamidoisoxazole; 3,4-Dimethylisoxazole-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulphanilamide; 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide; 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulphonamide; 5-(4-Aminophenylsulfonamido)-3,4-dimethylisoxazole; 5-(p-Aminobenzenesulfonamido)-3,4-dimethylisoxazole; 5-(p-Aminobenzenesulphonamido)-3,4-dimethylisoxazole; 5-Sulfanilamido-3,4-dimethylisoxazole; 5-Sulphanilamido-3,4-dimethyl-isoxazole; N'-(3,4)Dimethylisoxazol-5-yl-sulphanilamide; N1-(3,4-dimethyl-5-isoxazolyl)sulfanilamide; N1-(3,4-dimethyl-5-isoxazolyl)sulphanilamide; Sulfadimethylisoxazole; Sulfafurazol; Sulfafurazole; Sulfaisoxazole; Sulfasoxazole; Sulfisonazole; Sulfisoxasole; Sulfisoxazol; Sulfisoxazole; Sulfofurazole; Sulphadimethylisoxazole; Sulphafurazol; Sulphafurazole; Sulphaisoxazole; Sulphisoxazol; Sulphofurazole |
| Molecular Formula: | C11H13N3O3S |
| SMILES: | CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C |
| Structure: |
|
| DrugBank Description: | A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. |
| CAS Number: | 127-69-5 |
| Molecular Weight: | 267.304 |
| DrugBank Indication: | For the treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections. |
| DrugBank Pharmacology: | Sulfisoxazole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of <i>p</i>-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus. |
| DrugBank MoA: | Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid. |
| Targets: | Dihydropteroate synthase inhibitor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|